Currently, the major biomarkers used in CRC clinical management are KRAS/NRAS, and BRAF oncogene mutations which predict resistance to anti-EGFR therapy in metastatic CRC (mCRC). This evidence concerns the gene KRAS and colorectal carcinoma.